Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 82

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 82
---
 allocated. 

14

The following table summarizes the major classes of assets and liabilities of Veracyte SAS that were deconsolidated as of August 1, 2025 (in thousands of dollars):AmountsCurrent assets:Cash and cash equivalents$2,845 Accounts receivable2,087 Supplies and inventory4,318 Prepaid expenses and other current assets3,751 Total current assets13,001 Property, plant and equipment, net804 Right-of-use assets, operating leases673 Total assets deconsolidated14,478 Current liabilities:Accounts payable(3,171)Accrued Liabilities(6,004)Total current liabilities(9,175)Operating lease liabilities(9,459)Total liabilities deconsolidated(18,634)Net liabilities deconsolidated$(4,156)The loss on deconsolidation was calculated as follows (in thousands of dollars):Nine Months Ended September 30,Net liabilities deconsolidated$(4,156)Release of accumulated translation adjustment8,295 Recording of accounts payable to subsidiary 769 Other expenses1,800 Net loss on deconsolidation$6,708 Net cash outflows arising from the deconsolidation of the subsidiary was $2.9 million during the nine months ended September 30, 2025 related to the balance of cash and cash equivalents deconsolidated. Accrued LiabilitiesAccrued liabilities consisted of the following (in thousands of dollars):  September 30, 2025December 31, 2024Accrued compensation expenses$26,952 $30,595 Accrued other21,421 13,231 Total accrued liabilities$48,373 $43,826 

4. Business Combination

On February 5, 2024, or the Closing Date, the Company acquired 100% of the outstanding equity interests of C2i, or the C2i Acquisition. C2i was a privately-held company that developed a novel method for estimating tumor burden in cancer 

15

Table of ContentsVERACYTE, INC.Notes to Financial Statements(unaudited)

patients by analyzing a patient’s cell free DNA sequence and offered post-treatment monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA. The consideration to acquire C2i was $100.2 million, comprised of $73.3 million in the form of approximately